These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 37986879)
21. Strengthening Existing Laboratory-Based Systems vs. Investing in Point-of-Care Assays for Early Infant Diagnosis of HIV: A Model-Based Cost-Effectiveness Analysis. McCann NC; Cohn J; Flanagan C; Sacks E; Mukherjee S; Walensky RP; Adetunji O; Maeka KK; Panella C; Chadambuka A; Mafaune H; Odhiambo C; Freedberg KA; Ciaranello AL J Acquir Immune Defic Syndr; 2020 Jul; 84 Suppl 1(1):S12-S21. PubMed ID: 32520910 [TBL] [Abstract][Full Text] [Related]
22. The clinical and economic impact of point-of-care CD4 testing in mozambique and other resource-limited settings: a cost-effectiveness analysis. Hyle EP; Jani IV; Lehe J; Su AE; Wood R; Quevedo J; Losina E; Bassett IV; Pei PP; Paltiel AD; Resch S; Freedberg KA; Peter T; Walensky RP PLoS Med; 2014 Sep; 11(9):e1001725. PubMed ID: 25225800 [TBL] [Abstract][Full Text] [Related]
23. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
24. Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa. Boyer S; Baudoin M; Nishimwe ML; Santos M; Lemoine M; Maradan G; Sylla B; Kouanfack C; Carrieri P; Mourad A; Rouveau N; Moh R; Seydi M; Attia A; Woode ME; Lacombe K BMC Health Serv Res; 2022 Mar; 22(1):303. PubMed ID: 35248039 [TBL] [Abstract][Full Text] [Related]
25. Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses. Tu JJ; Kumar A; Giorgi EE; Eudailey J; LaBranche CC; Martinez DR; Fouda GG; Moreau Y; Thomas A; Montefiori D; Gao F; Sagar M; Permar SR J Virol; 2022 Jun; 96(11):e0023122. PubMed ID: 35536018 [TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of Routine Provider-Initiated Testing and Counseling for Children With Undiagnosed HIV in South Africa. Stanic T; McCann N; Penazzato M; Flanagan C; Essajee S; Freedberg KA; Doherty M; Putta N; Myer L; Siberry GK; Collins IJ; Vojnov L; Abrams E; Soeteman DI; Ciaranello AL Open Forum Infect Dis; 2022 Jan; 9(1):ofab603. PubMed ID: 35028333 [TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight African countries. Sweat MD; O'Reilly KR; Schmid GP; Denison J; de Zoysa I AIDS; 2004 Aug; 18(12):1661-71. PubMed ID: 15280777 [TBL] [Abstract][Full Text] [Related]
29. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa. Levison JH; Wood R; Scott CA; Ciaranello AL; Martinson NA; Rusu C; Losina E; Freedberg KA; Walensky RP Clin Infect Dis; 2013 Feb; 56(4):587-97. PubMed ID: 23087386 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of four chemotherapy regimens for treatment of advanced AIDS-associated Kaposi sarcoma in Kenya: a cost-effectiveness analysis. Freeman EE; McCann NC; Semeere A; Reddy KP; Laker-Oketta M; Byakwaga H; Pei PP; Hajny Fernandez ME; Kiprono S; Busakhala N; Martin JN; Maurer T; Bassett IV; Freedberg KA; Hyle EP Lancet Glob Health; 2022 Aug; 10(8):e1179-e1188. PubMed ID: 35839816 [TBL] [Abstract][Full Text] [Related]
31. Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies. Williams WB; Wiehe K; Saunders KO; Haynes BF J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25831. PubMed ID: 34806332 [TBL] [Abstract][Full Text] [Related]
32. 18-month occurrence of severe events among early diagnosed HIV-infected children before antiretroviral therapy in Abidjan, Côte d'Ivoire: a cohort study. Harambat J; Fassinou P; Becquet R; Touré P; Rouet F; Dabis F; Msellati P; Blanche S; Timité-Konan M; Salamon R; Leroy V; BMC Public Health; 2008 May; 8():169. PubMed ID: 18492259 [TBL] [Abstract][Full Text] [Related]
33. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. Armstrong EP J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326 [TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa. Glaubius RL; Hood G; Penrose KJ; Parikh UM; Mellors JW; Bendavid E; Abbas UL Clin Infect Dis; 2016 Aug; 63(4):539-47. PubMed ID: 27193745 [TBL] [Abstract][Full Text] [Related]
35. Costs and Scale-Up Costs of Integrating HIV Self-Testing Into Civil Society Organisation-Led Programmes for Key Populations in Côte d'Ivoire, Senegal, and Mali. d'Elbée M; Traore MM; Badiane K; Vautier A; Simo Fotso A; Kabemba OK; Rouveau N; Godfrey-Faussett P; Maheu-Giroux M; Boily MC; Medley GF; Larmarange J; Terris-Prestholt F Front Public Health; 2021; 9():653612. PubMed ID: 34109146 [TBL] [Abstract][Full Text] [Related]
36. Preliminary cost-effectiveness analysis of an AIDS vaccine in Abidjan, Ivory Coast. Cowley P Health Policy; 1993 May; 24(2):145-53. PubMed ID: 10128800 [TBL] [Abstract][Full Text] [Related]
37. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness. Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936 [TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. Walensky RP; Ross EL; Kumarasamy N; Wood R; Noubary F; Paltiel AD; Nakamura YM; Godbole SV; Panchia R; Sanne I; Weinstein MC; Losina E; Mayer KH; Chen YQ; Wang L; McCauley M; Gamble T; Seage GR; Cohen MS; Freedberg KA N Engl J Med; 2013 Oct; 369(18):1715-25. PubMed ID: 24171517 [TBL] [Abstract][Full Text] [Related]
39. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes. Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423 [TBL] [Abstract][Full Text] [Related]
40. Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants. McFarland EJ; Cunningham CK; Muresan P; Capparelli EV; Perlowski C; Morgan P; Smith B; Hazra R; Purdue L; Harding PA; Theron G; Mujuru H; Agwu A; Purswani M; Rathore MH; Flach B; Taylor A; Lin BC; McDermott AB; Mascola JR; Graham BS; J Infect Dis; 2021 Dec; 224(11):1916-1924. PubMed ID: 34009371 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]